Search Results for 'Diabetic foot ulcer'

In Ireland, a nation with approximately 300,000 people living with diabetes, the incidence of amputations among diabetic patients has reached a concerning level.

In Ireland, a nation with approximately 300,000 people living with diabetes, the incidence of amputations among diabetic patients has reached a concerning level. Reports indicate that 671 patients underwent amputations due to diabetic foot ulcers (DFUs) last year, which not only results in life-altering consequences for individuals but also poses a significant economic burden on the healthcare system. These statistics emphasize the importance of implementing this evidence-based treatment to tackle this growing crisis.

REMEDI, The Regenerative Medicine Institute at NUI Galway and Orbsen Therapeutics have entered into an agreement with Cardium Therapeutics to utilise Cardium’s Excellagen® pharmaceutically-formulated gel as a delivery agent for Orbsen Therapeutics’ proprietary stromal cell therapy in pre-clinical studies for the potential treatment of diabetic foot ulcers.